Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7)-Pipeline Review, H1 2017

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7)-Pipeline Review, H1 2017


  • Products Id :- GMDHC0899TDB
  • |
  • Pages: 42
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7)-Pipeline Review, H1 2017

Summary

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7)-Metabotropic glutamate receptor 7 is a protein encoded by the GRM7 gene. G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase.

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 3 and 1 respectively. Report covers products from therapy areas Central Nervous System, Ear Nose Throat Disorders and Genetic Disorders which include indications Post-Traumatic Stress Disorder (PTSD), Anxiety Disorders, Acute Sensorineural Hearing Loss, Acute Stress Disorder, Attention Deficit Hyperactivity Disorder (ADHD), Autism, DiGeorge Syndrome, Generalized Anxiety Disorder (GAD), Infantile Spasm (West Syndrome), Obsessive-Compulsive Disorder, Presbycusis, Status Epilepticus, Substance (Drug) Abuse and Visceral Pain.

The latest report Metabotropic Glutamate Receptor 7-Pipeline Review, H1 2017, outlays comprehensive information on the Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7)

The report reviews Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics and enlists all their major and minor projects

The report assesses Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7)-Overview

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7)-Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Aevi Genomic Medicine Inc

Bio-Pharm Solutions Co Ltd

Pragma Therapeutics SAS

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7)-Drug Profiles

ADX-71743-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fasoracetam-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JBPOS-0101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PGT-117-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize mGluR7 for Acute Sensorineural Hearing Loss and Presbycusis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize mGluR7 for Central Nervous System Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7)-Dormant Products

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7)-Product Development Milestones

Featured News & Press Releases

Apr 20, 2017: Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD

Apr 12, 2017: Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD

Mar 20, 2017: Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001

Jan 31, 2017: Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome

Jan 04, 2017: Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGluR+ ADHD Adolescents

Oct 29, 2016: Medgenics Presents New Data Showing Prevalence of Genetic Mutations in Pediatric Populations with Attention Deficit Hyperactivity Disorder

Sep 01, 2016: PRAGMA Therapeutics and UK Ministry of Defences Center for Defence Enterprise collaborate to support preclinical research on innovative treatment for tinnitus

Jun 17, 2016: Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD

Jun 13, 2016: Addex mGluR7 Program Demonstrate Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseases

Apr 25, 2016: PRAGMA Therapeutics awarded first prize and 300,000 from UK charity Action on Hearing Loss to develop new drugs to treat Hearing Loss

Nov 23, 2015: Addex and CHUV-UNIL Collaborators Awarded Swiss Grant to Advance Addex mGluR7 Allosteric Modulator for Neurodegenerative and Psychiatric Diseases

Nov 23, 2015: The SEVEN4PTSD consortium led by PRAGMA Therapeutics awarded 2015 French ANR grant to further advance its mGlu7 program for Post-Traumatic Stress Disorder

Dec 20, 2012: Addex Scientists Discover And Characterize First Potent And Selective Small Molecule Negative Allosteric Modulator Targeting mGlu7 Receptor

Oct 02, 2012: Addex Therapeutics And Collaborators Receive CHF700,000 Grant To Develop Allosteric Modulators For Neurodegenerative And Psychiatric Diseases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indication, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by Addex Therapeutics Ltd, H1 2017

Pipeline by Aevi Genomic Medicine Inc, H1 2017

Pipeline by Bio-Pharm Solutions Co Ltd, H1 2017

Pipeline by Pragma Therapeutics SAS, H1 2017

Dormant Projects, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Addex Therapeutics Ltd

Aevi Genomic Medicine Inc

Bio-Pharm Solutions Co Ltd

Pragma Therapeutics SAS

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) Therapeutic Products under Development, Key Players in Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) Therapeutics, Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) Pipeline Overview, Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) Pipeline, Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) Pipeline Assessment

select a license
Single User License
USD 3500 INR 249270
Site License
USD 7000 INR 498540
Corporate User License
USD 10500 INR 747810

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com